发明授权
EP2513311B1 PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF
有权
通过常规树突状细胞的IFN-拉姆达的制备，及其用途
- 专利标题： PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF
- 专利标题（中）： 通过常规树突状细胞的IFN-拉姆达的制备，及其用途
-
申请号： EP10795952.0申请日： 2010-12-17
-
公开(公告)号： EP2513311B1公开(公告)日： 2017-04-12
- 发明人: HOCHREIN, Hubertus
- 申请人： Bavarian Nordic A/S
- 申请人地址： Hejreskovvej 10 A 3490 Kvistgaard DK
- 专利权人： Bavarian Nordic A/S
- 当前专利权人： Bavarian Nordic A/S
- 当前专利权人地址： Hejreskovvej 10 A 3490 Kvistgaard DK
- 代理机构： Bendiksen, Henrik
- 优先权： US287777P 20091218; EP10005348 20100521
- 国际公布： WO2011072871 20110623
- 主分类号： C12N15/117
- IPC分类号： C12N15/117 ; A61P37/04 ; A61K35/15
摘要：
In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and/or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.
公开/授权文献
信息查询
IPC分类:
